Cargando…
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Antibody drug-conjugates (ADCs) have revolutionized the treatment of many types of cancer, including breast cancer. Recently, two new ADCs have been approved, trastuzumab deruxtecan and sacituzumab govitecan; both have demonstrated impressive improvements in overall survival, trastuzumab deruxtecan...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122624/ https://www.ncbi.nlm.nih.gov/pubmed/36966267 http://dx.doi.org/10.1007/s11864-023-01072-5 |